According to an article in Germany, Valneva expects to have provided all data to the authorities within the next weeks, allowing for an approval in the first quarter. There were rumours that Valneva has problems to get approval in the EU because they have not got the YES yet, but this is totally nonsens. Valneva always said that they expect approval in the first quarter of 2022 and to start distributing the vaccine to the EU as early as April. According to the CEO, Valneva has produced enough of the vaccine to start distributing it immediately after the approval. So, for now, everything is still on track! For me, VLA2001 has two major advantages over mRNA, safety AND duration of protection - this will lead, if Covid vaccinations will be needed in the next few years, to great interest of people that do not want to have a mRNA shot every 4-5 months!
A
I just had covid, not vaccinated. if the data shows that Valnevas vaccine works well against omikron and wider spectrum of COVID-19 variants with low risk of issues that mRNA vaccines obviously have, I will definitely consider a shot next season to hopefully be less prone to having it and less sick.
D
People who succeed in the stock market also accept periodic losses, setbacks, and unexpected occurrences. Calamitous drops do not scare them out of the game.
B
Somebody tell me why this is up 45% and Novavax (non mRNA vaccine, already approved and shipping in EU) is down day after day??
D
SABS - P3 also started and P2 data shows it has remarkable safety features.
S
It will! All over Europe news about Valneva! Production in Scotland since months. The stock is ready to rock!
Hello I'm new in bitcoin and i have been making huge losses but i recently see a lot of people earning from it. Can someone please tell me what I'm doing wrong
L
Some clever "Journalist" managed to ask 2 questions at EU briefing just now. She firstly asked about VALNEVA vaccine progress and , "reading between the lines" I believe Dr Cavallari's reply hinted that although he could not say at that time (did not want to) that it IS going to be authorised, but maybe this will take month or maybe 2 more . Not certain but for sure was at least positive.
Then the "Journalist" said she had asked wrong question (lol yeh sure !!) and meant to ask about NOVAVAX so he (EU) replied to that and said shipments of NOVAVAX vaccine are ON TARGET for delievery to EU in 1st quarter this year for sure.
Anyway thank you female "Journalist" whoever who are !.
m
Traders in Europe missing out on this pump, around 30pc up today …. Think I would sell and buy back in a week or 2. Good luck
L
** The European Medicines Agency (EMA) on Tuesday said the firm's COVID-19 vaccine was under an EU rolling review, but it was still awaiting some additional data ** "I think that was very badly interpreted by the market," an analyst told Reuters, pointing to a market over reaction ** The broker notes the submission for the vaccine is a rolling one, meaning the company must provide clinical data as it goes along ** Additionally, on the Nasdaq Index .NDX "all the biotech stocks have fallen sharply, so I think it's a continuation of that," the broker adds
L
I cannot say more than IF the Market OR Yourself has acted to sell on the basis of what was said at the Briefing then Market/You is I can say 101% WRONG . All that was said was that the Rolling Review is carrying on as planned as time to time data will be give to EMA by VALNEVA. I say nothing more than that. I am taking advantage to make extra 15% by Buying more.
E
Just reading about the fact the WHO says it does not support the strategy for continuing giving booster shots. Better to develop new vaccins that stop the transmission of COVID! No actual source but it is in our online newspaper as recent mentioned as LIVE news 🙏🏻 It would make sense for me! And Valneva obviously.
D
GRITSTONE also announced that their P1 trials neutralize Omicron variants. Not too much enthusiasm for real vaccines.!!
l
Do you guys ever use (http://Achieverspot.tech)? It is way better than trading VALN all day. Their tips actually go up! Haha
D
Rolled the dice yesterday. I knew I was gambling. Great vaccine for the flue
g
Updated OmiCron BNTX vaccine to deliver in March. NVAX and Moderna in April. Valneva April too? No way, very plausible because by that time they are not ready to manufacture and logistics.
S
Correct me if I'm wrong but 3 doses of Pfizer gave equivalent levels of neutralizing ABs against Omi as it did against the wild type strain (study in Dec using the same assay as Valneva) while 3 doses of Valneva give a 16.7-fold REDUCTION in titre vs the wild type levels. Given that the Pfizer wild type titer was already superior to Valneva then today's results are actually bad for Valneva and put them even more behind.
So I don't expect this pump to hold, especially given that Pfizer will soon bring out updated Omi-specific jabs that will need less doses to have equivalent wild type titer. Doesn't mean money can't be made on the misunderstanding though!
L
PARIS, Jan 4 - Shares in biotech company Valneva VLS.PA were suspended briefly on the Paris stock market on Tuesday after dropping sharply.
Valneva's share price has fluctuated in the past few weeks on news about the company's COVID-19 vaccine candidate. It is awaiting regulatory approval of the shot in the European Union and Britain.
Valneva shares recorded a drop of 23% on Tuesday afternoon before trading was suspended. Trading resumed later and by 1620 GMT the stock was down 23.4%.
At their lowest point on Tuesday, Valneva shares were trading at 17.17 euros ($19.38), the lowest since October last year.
V
If you had been more conspiracy theorist and better informed, you would not be losing your money right now.
There were rumours that Valneva has problems to get approval in the EU because they have not got the YES yet, but this is totally nonsens.
Valneva always said that they expect approval in the first quarter of 2022 and to start distributing the vaccine to the EU as early as April. According to the CEO, Valneva has produced enough of the vaccine to start distributing it immediately after the approval.
So, for now, everything is still on track!
For me, VLA2001 has two major advantages over mRNA, safety AND duration of protection - this will lead, if Covid vaccinations will be needed in the next few years, to great interest of people that do not want to have a mRNA shot every 4-5 months!
Then the "Journalist" said she had asked wrong question (lol yeh sure !!) and meant to ask about NOVAVAX
so he (EU) replied to that and said shipments of NOVAVAX vaccine are ON TARGET for delievery to EU in 1st quarter this year for sure.
Anyway thank you female "Journalist" whoever who are !.
** "I think that was very badly interpreted by the market," an analyst told Reuters, pointing to a market over reaction
** The broker notes the submission for the vaccine is a rolling one, meaning the company must provide clinical data as it goes along
** Additionally, on the Nasdaq Index .NDX "all the biotech stocks have fallen sharply, so I think it's a continuation of that," the broker adds
I say nothing more than that. I am taking advantage to make extra 15% by Buying more.
So I don't expect this pump to hold, especially given that Pfizer will soon bring out updated Omi-specific jabs that will need less doses to have equivalent wild type titer. Doesn't mean money can't be made on the misunderstanding though!
VLS.PA were suspended briefly on the Paris stock market on
Tuesday after dropping sharply.
Valneva's share price has fluctuated in the past few weeks
on news about the company's COVID-19 vaccine candidate. It is
awaiting regulatory approval of the shot in the European Union
and Britain.
Valneva shares recorded a drop of 23% on Tuesday afternoon
before trading was suspended. Trading resumed later and by 1620
GMT the stock was down 23.4%.
At their lowest point on Tuesday, Valneva shares were
trading at 17.17 euros ($19.38), the lowest since October last
year.